Climate Change Data

Alnylam Pharmaceuticals, Inc.

Climate Impact & Sustainability Data (2020, 2021, 2022, 2023)

Reporting Period: 2020

Environmental Metrics

Waste Generated:992,000 pounds of hazardous materials (2020)

ESG Focus Areas

  • Patients
  • Science
  • Employees
  • Communities
  • Planet
  • Governance and Integrity

Environmental Achievements

  • Initiated a process to collect baseline data on energy consumption, greenhouse gas emissions, and other environmental impacts.
  • Installed an energy-efficient HVAC system designed to save 126,000 KWH per year and 2.65M lbs. of steam per year at headquarters.
  • Upgraded lighting to intelligent LED lights at headquarters, increasing efficiency by up to 80%.
  • Installed an HVAC energy recovery system at headquarters to reduce heating and cooling demands.
  • Constructed Norton, MA facility with leading-edge passive building and mechanical insulation systems to maximize energy efficiency.
  • Norton facility boiler plant uses state-of-the-art combustion technologies and heat recovery systems to minimize emissions.
  • Reduced CO2 emissions by 100 metric tons in France and Germany operations by switching to group deliveries and eliminating insulated shippers.
  • Recycled 440 gallons of waste ethanol from Alewife, MA site.

Social Achievements

  • Launched a new strategic framework to formalize and structure Alnylam’s Corporate Responsibility activities.
  • Appointed the first Chief Diversity, Equity & Inclusion (DE&I) Officer.
  • Senior leaders participated in unconscious-bias training and racial awareness initiatives.
  • Developed strategies and approaches to increase the inclusion of BIPOC groups in clinical trials.
  • Hosted the first annual Global Rare Disease Patient Advocacy Collaborative Summit.
  • Provided support for commercially insured patients to afford medicine through the Commercial Copay Program.
  • Facilitated home-based infusions for patients during the COVID-19 pandemic.
  • Expanded genetic testing offerings to Canada and Brazil.
  • Released the first annual U.S. Rare Disease Trend Report.
  • Launched a new series of virtual programs with Black Health Matters (BHM) to increase disease awareness in the Black community.
  • Donated $250,000 to the Boston Resiliency Fund to provide food for children and seniors, technology to aid remote learning for students, and assistance to first responders and healthcare workers.
  • Donated $25,000 to the Life Sciences Cares COVID-19 Response Fund.
  • Donated protective equipment (PPE) and lab supplies to MassBio’s supply hub and the Biotechnology Innovation Organization’s (BIO) emergency efforts.
  • Invested $250,000 in renovations to Henri A. Termeer Square.
  • Raised and donated a total of $275,000 from the “Power of Silencing” silent auction.
  • Provided a total of $520,000 to 14 patient advocacy groups across the globe through Advocacy for Impact grants.
  • Made a $50,000 donation to Science from Scientists to inspire the next generation to solve real-world problems through STEM literacy.

Governance Achievements

  • Formalized a Patient-Focus Working Group.
  • Established an internal audit function reporting to the Audit Committee of the Board of Directors.
  • Continued delivery of interactive Unconscious Bias training and introduced Understanding Race & Ethnicity in the Workplace training.
  • Developed a Global Procurement Policy to ensure ethical and responsible purchasing.
  • Signed the MassBio CEO Pledge for a More Equitable and Inclusive Life Sciences Industry.
  • Signed the U.S. New Commitment to Patients and the European Biotech Social Pact.

Climate Goals & Targets

Medium-term Goals:
  • Establish baseline metrics on energy usage and greenhouse gas emissions across Alnylam’s operations globally (beginning in 2022).
Short-term Goals:
  • Establish baseline metrics on solid waste across Alnylam’s operations globally.
  • Expand conversations with landlords of leased offices on sustainability.
  • Expand GoGreen Commercial Fleet management practices.
  • Reduce personal use plastics in global offices.
  • Increase by 20% the overall number of Black and Latinx individuals that make up our U.S. employee base at all levels.
  • Integrate Unconscious Bias training for people managers into the company’s core training curriculum.
  • Roll out Understanding Race & Ethnicity in the Workplace trainings across all levels globally.
  • Launch the Athena Project female leadership accelerator program.
  • Launch Alnylam health equity-focused signature social impact program.
  • Relaunch our annual Community Service Day remotely and in-person.
  • Launch year three of Advocacy for Impact Grants Program.

Environmental Challenges

  • COVID-19 pandemic and its impact on employees, patients, and operations.
  • Addressing racial and social injustice.
  • Ensuring access and affordability of medicines.
  • Increasing representation of BIPOC groups in the workforce and clinical trials.
  • Understanding and mitigating Alnylam’s environmental footprint.
  • Managing the complexities of global operations and supply chains.
Mitigation Strategies
  • Implemented a comprehensive COVID-19 response strategy, including remote work options, enhanced benefits, and testing programs.
  • Launched diversity, equity, and inclusion initiatives, including unconscious bias training and the appointment of a DE&I officer.
  • Developed a Patient Access Philosophy and implemented programs to improve access and affordability.
  • Developed strategies to increase participation of minority populations in clinical trials.
  • Initiated data collection on environmental impacts and developed plans to establish tracking and measurement tools.
  • Built a network of trusted distribution partners to extend access to medicines in countries without Alnylam operations.

Supply Chain Management

Responsible Procurement
  • Supplier compliance with ethics, safety, quality, anti-corruption, information security, and non-disclosure policies.

Climate-Related Risks & Opportunities

Reporting Period: 2021

Environmental Metrics

Total Carbon Emissions:11411 tCO2e/year (2020 baseline)
Scope 1 Emissions:3985 tCO2e/year (2020)
Scope 2 Emissions:7443 tCO2e/year (2020)
Scope 3 Emissions:3133 tCO2e/year (2020)
Total Energy Consumption:22133 MWh/year (2020)
Waste Generated:208 tons/year (2020 baseline)
Carbon Intensity:23 MTCO2e per $MM revenue (2020)

ESG Focus Areas

  • Patients
  • Science
  • Employees
  • Communities
  • Planet
  • Governance and Integrity

Environmental Achievements

  • Completed LED lighting upgrade at Alewife manufacturing facility, resulting in reduced maintenance and energy savings.
  • Improved reliability and efficiency of the central cooling system at the Norton manufacturing site through 'free cooling'.

Social Achievements

  • Launched Alnylam Challengers with a $1 million investment in Acumen America to address health inequalities.
  • Expanded family leave options to include general caregiving leave of up to 12 weeks.
  • Achieved 20% year-over-year increase in Black or African American and Hispanic or Latino individuals in the U.S. employee base.

Governance Achievements

  • Formalized a CR Steering Committee structure with Working Groups for each focus area.
  • Completed a materiality assessment to understand stakeholder and business priorities.
  • Developed a Supplier Code of Conduct and a Supplier Diversity program (to be fully implemented in 2022).

Climate Goals & Targets

Long-term Goals:
  • Not disclosed
Medium-term Goals:
  • Model GHG and operational waste reduction targets.
  • Develop a roadmap to approve, implement, and communicate our emissions reduction strategy.
Short-term Goals:
  • Complete 2021 Scope 1, 2, and 3 GHG and solid/hazardous waste inventory.
  • Complete baseline data collection and analysis of water use.
  • Conduct third-party verification of baseline and 2021 data.

Environmental Challenges

  • Understanding and mitigating Alnylam's growing global environmental footprint.
  • Addressing health inequities and social determinants of health.
  • Increasing diversity in clinical trials.
Mitigation Strategies
  • Launched a comprehensive process to understand, quantify, and mitigate GHG emissions and waste management.
  • Partnered with Acumen America to address health inequalities.
  • Assembled a team to increase diversity in trial design and execution, employing tools like e-consent and virtual visits.

Supply Chain Management

Supplier Audits: Annual quality audit for all suppliers

Responsible Procurement
  • Global Procurement Policy
  • Supplier Code of Conduct (to be fully implemented in 2022)
  • Supplier Diversity program (to be fully implemented in 2022)

Climate-Related Risks & Opportunities

Reporting Standards

Frameworks Used: GRI Standards: Core option, SASB Biotechnology & Pharmaceuticals Standard

Awards & Recognition

  • Boston Globe’s “Top Places to Work” (2021)

Reporting Period: 2022

Environmental Metrics

Total Carbon Emissions:15,130 tCO2e (2021)
Scope 1 Emissions:3,968 tCO2e (2021)
Scope 2 Emissions:9,074 tCO2e (2021)
Scope 3 Emissions:2,135 tCO2e (2021)
Renewable Energy Share:Not disclosed
Total Energy Consumption:22,657 MWh (2021)
Water Consumption:13.8 million gallons (2021)
Waste Generated:Not disclosed
Carbon Intensity:Not disclosed

ESG Focus Areas

  • Patients
  • Science
  • Employees
  • Communities
  • Planet
  • Governance

Environmental Achievements

  • Took significant steps to quantify and mitigate our global environmental footprint; worked to better understand our greenhouse gas (GHG) emissions profile, use of water, and waste management process
  • Completed a lighting upgrade in Zug, Switzerland office, resulting in a 30-40% reduction in energy use
  • Fully transitioned to EcoTek® biodegradable gloves across laboratories, manufacturing and operations

Social Achievements

  • Launched fifth product within four years and demonstrated positive results in clinical trials
  • Evolved approach to outreach and inclusion within clinical trials, setting diversity goals and training clinical operations team in cultural competency
  • Met all six comprehensive goals outlined in MassBio’s Diversity, Equity and Inclusion (DE&I) public pledge; launched a formal supplier diversity program, resulting in more than $24 million spend with diverse suppliers
  • Expanded Alnylam Challengers global Community Impact Initiative to European country teams, focusing on refugee populations
  • Named one of Newsweek’s Most Responsible Companies in the U.S., a Gold Team Massachusetts Economic Impact Award winner, and named to the Bloomberg Gender-Equality Index for the 3rd year in a row
  • Named to The Boston Globe’s Top Places to Work for the 8th year in a row, and recognized by Science Magazine as Top Employer for 4th year in a row; named one of Fortune Magazine’s Best Workplaces for Women for the first time

Governance Achievements

  • Appointed a Chief Ethics & Compliance Officer; launched local Compliance Committees across countries and regions, and appointed over 40 Global Compliance Champions
  • Launched inaugural Integrity Week

Climate Goals & Targets

Long-term Goals:
  • Not disclosed
Medium-term Goals:
  • Not disclosed
Short-term Goals:
  • Increase the overall number of Black or African American and Hispanic/Latino individuals in our U.S. employee base by 20% YOY
  • Grow female representation within Senior Leadership Team (SLT) by 20% relative to 2022
  • Ensure at least 50% of Alnylam’s interns are hired through external partner programs Posse or Project Onramp
  • Obtain >90% favorable rating in key DE&I questions within company culture survey
  • Expand components of the Alnylam Challengers social impact program globally
  • Increase by 10% YOY participation of Alnylam employees participating in Global Week of Service
  • Expand the number and variety of volunteer and giving opportunities through Benevity
  • Develop strategic plan for a corporate match program for employee charitable donations

Environmental Challenges

  • Increase in injury rate to 1.30 in 2022, largely due to work-related COVID-19 cases resulting from return to pre-pandemic travel and work initiatives
Mitigation Strategies
  • Continued monitoring and mitigation of safety risks across the company; conducted audits and gap analyses of key sites; launched first workers council in France; launched a new focus on occupational health in international regions

Supply Chain Management

Supplier Audits: Annual quality audits for all suppliers

Responsible Procurement
  • Global Procurement Policy
  • Supplier Code of Conduct

Climate-Related Risks & Opportunities

Physical Risks
  • Not disclosed
Transition Risks
  • Not disclosed
Opportunities
  • Not disclosed

Reporting Standards

Frameworks Used: GRI Standards: Core Option, SASB Biotechnology & Pharmaceuticals Standard

Certifications: Null

Third-party Assurance: Not disclosed

UN Sustainable Development Goals

  • Not disclosed

Not disclosed

Sustainable Products & Innovation

  • Not disclosed

Awards & Recognition

  • Newsweek’s Most Responsible Companies
  • Gold Team Massachusetts Economic Impact Award
  • Bloomberg Gender-Equality Index
  • The Boston Globe’s Top Places to Work
  • Science Magazine Top Employer
  • Fortune Magazine’s Best Workplaces for Women
  • Science Club for Girls Catalyst Award

Reporting Period: 2023

Environmental Metrics

Total Carbon Emissions:13547 tCO2e/year (Scope 1+2 market-based)
Scope 1 Emissions:3529 tCO2e/year
Scope 2 Emissions:9933 tCO2e/year (market-based)
Scope 3 Emissions:2133 tCO2e/year (select categories)
Renewable Energy Share:100% at Norton and Alewife facilities (as of January 2024)
Total Energy Consumption:24588 MWh/year
Water Consumption:15.2 million gallons/year
Waste Generated:505 tons/year (Municipal Solid Waste)
Carbon Intensity:Not disclosed

ESG Focus Areas

  • Patients
  • Science
  • Employees
  • Communities
  • Planet
  • Governance

Environmental Achievements

  • Sourcing renewable energy for Norton and Alewife facilities, resulting in zero Scope 2 market-based GHG emissions at both sites.
  • 7% reduction in water consumption at Norton facility in 2023.
  • 27% year-over-year savings in electricity at Zug office due to LED lighting.

Social Achievements

  • Grew female representation within Senior Leadership Team (SLT) from 32% in 2022 to 37% in 2023.
  • Grew hiring of women across the organization from 55% in 2022 to 60% in 2023.
  • 90% of Alnylam employees believe the company supports a diverse workplace.
  • Over 1,000 employees donated more than 3,000 hours across 48 volunteer projects during Global Community Service Week (20% increase in hours over 2022).
  • Launched three corporate matching initiatives for humanitarian giving, engaging more than 50% of Alnylam employees in volunteerism in 2023.

Governance Achievements

  • Achieved 100% completion on Code of Business Conduct and Ethics training for new employees.
  • Increased diverse supplier spend by 5%.

Climate Goals & Targets

Long-term Goals:
  • Not disclosed
Medium-term Goals:
  • Achieve Alnylam P5x25 strategy goals (Patients: Over 0.5 million on Alnylam RNAi medicines globally; Products: 6+ marketed products in rare and prevalent diseases; Pipeline: Over 20 clinical programs, with 10+ in late stages and 4+ INDs per year; Performance: ≥40% revenue CAGR through YE 2025; Profitability: Achieve sustainable non-GAAP profitability within the period).
Short-term Goals:
  • Continue Scope 1 and 2 GHG emissions calculation and work toward determining baseline year.
  • Increase diverse supplier spend 5% in 2024.

Environmental Challenges

  • Decreased understanding of Alnylam's vision for the future among employees (85% favorable responses in 2023 vs. 99% in 2014).
  • Data gaps in water usage at some locations.
Mitigation Strategies
  • Focus on three key areas for continued improvement in 2024: clarity, community, and career.
  • Consistent estimation methodologies for water discharge data where gaps exist.

Supply Chain Management

Supplier Audits: Annual quality audits for all suppliers.

Responsible Procurement
  • Global Procurement Policy
  • Third Party Code of Conduct
  • Supplier Diversity Program

Climate-Related Risks & Opportunities

Physical Risks
  • Not disclosed
Transition Risks
  • Not disclosed
Opportunities
  • Renewable energy sourcing, energy efficiency improvements.

Reporting Standards

Frameworks Used: GRI Standards: Core option, SASB Biotechnology & Pharmaceuticals Standard, UN Sustainable Development Goals (SDGs)

Certifications: Null

Third-party Assurance: Cameron-Cole (Limited Assurance for Scope 1 and 2 GHG Inventory)

UN Sustainable Development Goals

  • Not disclosed

Alnylam's work aligns with numerous UN SDGs, particularly those related to health, education, economic growth, and climate change.

Sustainable Products & Innovation

  • Not disclosed

Awards & Recognition

  • #1 on Boston Globe’s “Top Places to Work” (3 consecutive years)
  • HumanKind 100 Company (2 years in a row)
  • Boston Business Journal’s Corporate Citizenship Community Collaboration Award (2023)
  • Newsweek Most Responsible Companies (2 years in a row)
  • Communique Award for Leadership Action on Workforce Diversity & Inclusion (2023)